UBS and Goldman Sachs raised price targets for MMM, while Jim Cramer discussed the company's turnaround efforts.
2 reports, 1 independent
Updated Jul 25
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS and Goldman Sachs raised price targets for MMM, while Jim Cramer discussed the company's turnaround efforts.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
UBS
Swiss multinational investment bank and financial services company
-
MMM
Russian company that perpetrated one of the world's largest Ponzi schemes of all time
Nothing else this week.
-
Goldman Sachs
American investment bank
Related events
- Multiple major banks, including Citigroup, UBS, Bank of America, and Barclays, have issued updated price targets and ratings.
- Assembly Biosciences stock traded on Nasdaq, while UBS cut its price target but maintained a Buy rating, following an SEC disclosure.
- Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.
- Banks like Mizuho, Deutsche Bank, and Goldman Sachs maintained or raised ratings for Harmony Biosciences, citing benefits from tariffs and onshoring trends for AI stocks.
Coverage
Newest first; wire copies grouped- insidermonkey.comJim Cramer Called 3M Company (NYSE:MMM) “Easy Money” As Earnings Hit The Wires